Deltex Medical Regulatory News (DEMG)

26 Mar 2008 07:02

Deltex Medical Group PLC26 March 2008 Deltex Medical Group plc CardioQ shown to halve average recovery times after major surgery 26 March 2008 - Deltex Medical Group plc ("Deltex Medical"), the UK's leadinghaemodynamic monitoring company, notes results from introducing a new approachto major surgery that includes routine use of the CardioQ. The article published in the March edition of Health Director, reports on astudy led by Mr Mike Parker, a senior consultant colorectal surgeon at DarentValley hospital in Kent and current President of the Association of LaparoscopicSurgeons of Great Britain and Ireland. The study reports on the impact ofintroducing combination of an enhanced recovery programme (including oesophagealDoppler monitoring with the CardioQ) and minimally invasive surgical techniques('laparoscopic' or 'keyhole' surgery) for patients undergoing major bowelsurgery. Conducted between January 2003 and June 2007, the study, monitored the timepatients spent in hospital and the time until they reported themselves feelingfully recovered (i.e. as well as they had felt before their operation). Datarecorded for 200 patients having laparoscopic surgery under the enhancedrecovery programme was compared to that for patients having open surgery undertraditional care pathways in the same hospital. The study found that the average enhanced recovery laparoscopic patient lefthospital after five days and was fully recovered after a further seven days, atotal recovery time of 12 days. By contrast, the average patient receivingtraditional care (open surgery, no CardioQ, no enhanced recovery programme) lefthospital after eleven days and was only fully recovered after another 29 days, atotal recovery time of 40 days. Mr Parker stated: "By enabling patients to leave hospital sooner and recover more quickly we aresaving the (NHS) trust a significant amount of money. For the third of patientswe treated who were returning to work we also saved the economy substantial sumsby enabling them to return to work a full three weeks earlier than before." Deltex Medical's Chief Executive, Andy Hill commented: "The combination of enhanced recovery programmes, keyhole surgery and theCardioQ is extremely powerful and this data will be of interest to doctors,patients, healthcare providers and health insurers in most developed healthcaresystems, including the in the USA." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 0207 554 1400Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6000Philip Davies philip.davies@csysecurities.comRussell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ(TM) monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already around 1,500 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange